2 Amendments of Kader ARIF related to 2010/2080(INI)
Amendment 5 #
Draft opinion
Paragraph 2
Paragraph 2
2. Recalls that, whereas some counterfeit products constitute a threat to consumers’ interests and safety, public health and the environment, the fight against counterfeiting should not affect access to legitimate, affordable and safe medicinal products; calls upon the Commission, the Council and the Member States to refrain from expanding the definition of the notion of ‘counterfeiting’ beyond the scope of deliberate trademark violations which potentially damage consumers’ interests and safety, public health and the environment, and warns against the parallel expansion of the scope of criminal law; recalls that other IPR violations such as copyright piracyinfringements on a non- commercial scale and patent infringements should remain governed by civil law; expresses great concern with regard to the criminalisation of patent infringements, which may be used as an obstacle to legitimate trade in generic medicines;
Amendment 7 #
Draft opinion
Paragraph 3
Paragraph 3
3. Reiterates its call upon the Commission to ensure that the European Parliament is kept immediately and fully informed of the advancement of ACTA negotiationsat all stages of the negotiations in order to respect the letter and spirit of the Lisbon Treaty, as well as its request for further reassurance that ACTA will not modify the EU acquis on IPR enforcement and fundamental rights; calls upon the Commission to engage closely with third countries which are not part of ACTA negotiations, in particular emerging countries;